Replimune Group (NASDAQ:REPL) Rating Increased to Buy at HC Wainwright

HC Wainwright upgraded shares of Replimune Group (NASDAQ:REPL) from a neutral rating to a buy rating in a report published on Monday morning, MarketBeat Ratings reports. HC Wainwright currently has $12.00 target price on the stock.

A number of other analysts have also weighed in on the stock. Leerink Partners raised shares of Replimune Group from a “market perform” rating to an “outperform” rating and raised their price target for the company from $3.00 to $13.00 in a report on Monday, October 20th. Barclays lowered shares of Replimune Group from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $17.00 to $3.00 in a report on Wednesday, July 23rd. Jefferies Financial Group lowered their price target on shares of Replimune Group from $31.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, July 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Replimune Group in a report on Tuesday, October 14th. Finally, Cantor Fitzgerald raised shares of Replimune Group from a “neutral” rating to an “overweight” rating in a report on Wednesday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $9.75.

Replimune Group Stock Up 6.0%

Shares of REPL opened at $9.33 on Monday. The stock has a market cap of $728.30 million, a price-to-earnings ratio of -2.88 and a beta of 0.42. The company has a quick ratio of 6.94, a current ratio of 6.94 and a debt-to-equity ratio of 0.21. Replimune Group has a 12 month low of $2.68 and a 12 month high of $17.00. The company has a 50-day moving average price of $5.44 and a two-hundred day moving average price of $7.33.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Equities analysts predict that Replimune Group will post -2.97 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Emily Luisa Hill sold 9,154 shares of Replimune Group stock in a transaction on Friday, August 15th. The shares were sold at an average price of $5.37, for a total transaction of $49,156.98. Following the transaction, the chief financial officer directly owned 134,368 shares of the company’s stock, valued at $721,556.16. This trade represents a 6.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Replimune Group by 6.6% during the first quarter. Vanguard Group Inc. now owns 3,833,033 shares of the company’s stock worth $37,372,000 after purchasing an additional 237,185 shares in the last quarter. Millennium Management LLC boosted its position in shares of Replimune Group by 2.8% during the first quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock worth $11,927,000 after purchasing an additional 33,574 shares in the last quarter. MPM Bioimpact LLC boosted its position in shares of Replimune Group by 3.9% during the first quarter. MPM Bioimpact LLC now owns 987,036 shares of the company’s stock worth $9,624,000 after purchasing an additional 37,036 shares in the last quarter. Parkman Healthcare Partners LLC boosted its position in shares of Replimune Group by 9.3% during the first quarter. Parkman Healthcare Partners LLC now owns 950,399 shares of the company’s stock worth $9,266,000 after purchasing an additional 80,640 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in shares of Replimune Group by 20.9% during the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock worth $6,729,000 after purchasing an additional 119,145 shares in the last quarter. 92.53% of the stock is owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.